In this video, health-care analyst David Williamson discusses Dendreon's recent third-quarter results. He focuses on why, despite the positive trends, Dendreon is far from out of the woods. Watch and find out why investors who bid up shares as much as 30% intraday on Friday may be missing the bigger picture.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Investors Should Be Concerned About Dendreon originally appeared on Fool.com.David Williamson owns shares of Johnson & Johnson. Follow him on Twitter, @MotleyDavid. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.